Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia (CML) in the BFORE trial: 18 month follow-up Meeting Abstract
| Authors: | Gambacorti-Passerini, C.; Deininger, M. W.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Dyagil, I.; Glushko, N.; Milojkovic, D.; le Coutre, P. D.; Gutierrez, V. G.; Crescenzo, R. J.; Leip, E.; Bardy-Bouxin, N.; Hochhaus, A.; Brummendorf, T. H.; Cortes, J. E. |
| Abstract Title: | Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia (CML) in the BFORE trial: 18 month follow-up |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419402146 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.896.896 |
| Notes: | Meeting Abstract: 896 -- Source: Wos |
